Anika Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Anika Therapeutics Focuses on Core HA Technology with Divestitures, Eyes U.S. Market Expansion
Anika Therapeutics shifts strategy to concentrate on osteoarthritis pain management and regenerative solutions, divesting Arthrosurface and Parcus Medical.
NASDAQ
Anika Therapeutics has filed an amendment to its annual report on Form 10-K, primarily to include information required in Part III regarding directors, executive officers, and corporate governance.
NASDAQ
Anika Therapeutics details executive retention agreements, director compensation policies, and subsidiary information in its latest 10-K filing with the SEC.